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Abstract
Background: a/b-hydrolase domain containing (ABHD)12 is a recently discovered serine hydrolase that acts in vivo as a
lysophospholipase for lysophosphatidylserine. Dysfunctional ABHD12 has been linked to the rare neurodegenerative
disorder called PHARC (polyneuropathy, hearing loss, ataxia, retinosis pigmentosa, cataract). In vitro, ABHD12 has been
implicated in the metabolism of the endocannabinoid 2-arachidonoylglycerol (2-AG). Further studies on ABHD12 function
are hampered as no selective inhibitor have been identified to date. In contrast to the situation with the other
endocannabinoid hydrolases, ABHD12 has remained a challenging target for inhibitor development as no crystal structures
are available to facilitate drug design.
Methodology/Principal Findings: Here we report the unexpected discovery that certain triterpene-based structures inhibit
human ABHD12 hydrolase activity in a reversible manner, the best compounds showing submicromolar potency. Based on
structure activity relationship (SAR) data collected for 68 natural and synthetic triterpenoid structures, a pharmacophore
model has been constructed. A pentacyclic triterpene backbone with carboxyl group at position 17, small hydrophobic
substituent at the position 4, hydrogen bond donor or acceptor at position 3 accompanied with four axial methyl
substituents was found crucial for ABHD12 inhibitor activity. Although the triterpenoids typically may have multiple protein
targets, we witnessed unprecedented selectivity for ABHD12 among the metabolic serine hydrolases, as activity-based
protein profiling of mouse brain membrane proteome indicated that the representative ABHD12 inhibitors did not inhibit
other serine hydrolases, nor did they target cannabinoid receptors.
Conclusions/Significance: We have identified reversibly-acting triterpene-based inhibitors that show remarkable selectivity
for ABHD12 over other metabolic serine hydrolases. Based on SAR data, we have constructed the first pharmacophore
model of ABHD12 inhibitors. This model should pave the way for further discovery of novel lead structures for ABHD12
selective inhibitors.
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Introduction
The serine hydrolase a/b-hydrolase domain containing
(ABHD)12 is a membrane-bound enzyme that together with
monoacylglycerol lipase (MAGL) and ABHD6 contributes to the
metabolism of the endocannabinoid 2-arachidonoylglycerol (2-
AG) in vitro [1]. In vivo, ABHD12 serves as a lysophospholipase
showing preference towards lysophosphatidylserine (LPS) in the
mammalian nervous system [2]. Even though ABHD12 is still
poorly characterized, recently developed ABHD122/2 mice have
shed some light to its possible physiological functions. In the study
of Blankman et al. (2013), ABHD12 deficient mice developed age-
dependent symptoms that resemble the human neurodegenerative
disorder PHARC (polyneuropathy, hearing loss, ataxia, retinosis
pigmentosa, cataract). Authors suggested that the disrupted LPS
metabolism and resulting neuroinflammation may form one of the
molecular basis for PHARC [3].
Tissue distribution and subcellular localization of MAGL,
ABHD6 and ABHD12 are different, suggesting that these
hydrolases could control different pools of 2-AG [1]. An active
site of ABHD12 is predicted to face the lumen and/or
extracellular space and in the latter position ABHD12 could
possibly metabolize extracellular pool of 2-AG. We have recently
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delineated the monoacylglycerol (MAG) substrate preferences of
ABHD12 in vitro and found that unlike MAGL, ABHD12 (and
ABHD6) prefers the 1(3)-isomers of unsaturated MAGs over the 2-
isomers [4]. More detailed pharmacological studies with ABHD12
have been limited due to the lack of selective inhibitor(s).
Preliminary inhibitor profiling has shown that the universal
lipase/serine hydrolase inhibitors tetrahydrolipstatin (THL, Figure
S1) and methyl arachidonyl fluorophosphonate (MAFP, Figure S1)
relatively potently inhibit ABHD12 [4]. ABHD12 has remained a
challenging target for inhibitor development as there are no crystal
structures available, number of known inhibitors is low and the
existing activity data are limited.
In order to find novel lead structures for selective inhibitors of
recently discovered serine hydrolases, exploring the activity of
natural compounds may offer valuable information for this
developing process. For instance, plant-derived pentacyclic triter-
penes such as betulinic, oleanolic and ursolic acid are interesting
molecules as they all are bioactive and widespread in nature and
their therapeutic potential is well documented [5–9] see also
reviews [10–16] and references cited therein. In addition, their
multi-targeting biological activity, low toxicity, easy availability,
and core structure offering good starting point for chemical
modifications, make triterpenoids appealing source for the drug
discovery. Along this line, recent studies have revealed that
triterpenes may include potential candidates for novel inhibitors of
e.g. endocannabinoid hydrolases. Indeed, pristimerin has been
shown to inhibit MAGL activity in in vitro studies [17,18]. In
another study, a mixture of a/b-amyrin (ursane and oleanane-type
triterpenoids, Figure S2) was shown to reduce inflammatory and
neuropathic hyperalgesia in mice through activation of the
cannabinoid CB1 (CB1R) and CB2 (CB2R) receptors [19].
Interestingly, despite their high affinity towards CB1R, the
compounds failed to show any cannabimimetic effects in the
tetrad test. In addition, a- and b-amyrin were reported to inhibit
2-AG-hydrolysis in pig brain homogenates [20]. The molecular
target of this action was not identified.
Our preliminary screening efforts to identify novel serine
hydrolase inhibitors among various chemical compounds revealed
unexpectedly that ursolic acid was able to selectively inhibit
ABHD12 with negligible effect on ABHD6 or MAGL activity.
Inspired by this finding, we selected various commercial
triterpenes/triterpenoids as well as recently reported betulin-based
triterpenes for further evaluation. In this paper, we report the
inhibitory activity of these compounds towards human ABHD12.
Based on the activity data we have established preliminary
structure-activity relationships (SAR) and constructed the first
pharmacophore model for betulin-based triterpenes. This model
should prove useful in the discovery of novel lead structures for
ABHD12 selective inhibitors. Although the triterpenoids typically
interact with multiple protein targets, we witnessed unprecedented
selectivity towards ABHD12 among the metabolic serine hydro-
lases, as activity-based protein profiling (ABPP) of mouse brain
membrane proteome indicated that the representative ABHD12
inhibitors did not inhibit other serine hydrolases, nor did they
target cannabinoid receptors.
Results and Discussion
Structure-activity relationship (SAR) studies
Pentacyclic triterpenes can be classified into three different
groups: lupanes, oleananes and ursanes. Derivatives of triterpenes
are called triterpenoids. In this study, commercially available
triterpenes 1–11 and triterpenoids 12–15 were purchased from
different chemical vendors and tested for their ability to inhibit
hydrolase activity in lysates of HEK293 cells transiently overex-
pressing human ABHD12 (hABHD12) [4]. The inhibition data
are presented in Table 1 (detailed chemical structures of the tested
compounds are presented in Figure S2). In the lupane series (1–3),
an importance of a carboxyl group at position 17 was shown as
betulinic acid (1) had the highest inhibitory activity
(IC50 = 2.5 mM). However, lipophilicity differences should also
be taken into consideration as the compound with the lowest logD
(Table 1) also had the highest inhibitory activity. In the ursane
series (4–6), similar effect of the carboxyl group at position 17 was
observed as ursolic acid (4) showed higher inhibition activity
compared to a-amyrin (6) that has a methyl group at this position.
Asiatic acid (5), which has a primary hydroxyl group at the
position 4, was completely devoid of activity, demonstrating the
importance of this position for hABHD12 inhibition. Notably,
asiatic acid had the highest water solubility of the entire series
which, in this case, did not lead to higher activity. Asiatic acid also
has an extra hydroxyl group at position 2. However, it can be
concluded that this hydroxyl group was actually favored as
maslinic acid (8) belonging to the oleanane series, had the same
substitution and this feature greatly improved the inhibitory
activity. In fact, among the 15 commercial compounds tested,
maslinic acid was the best hABHD12 inhibitor having an IC50
value of 1.3 mM. The oleanane series (7–11) further confirmed our
findings that dimethyl at position 4 in combination with a carboxyl
group at position 17 were important features for hABHD12
inhibition. Finally, we tested four triterpenoids, 2-cyano-3,12-
dioxo-oleana-1,9(11)-dien-28-oic acid (CDDO) (12), CDDO
methyl ester (13), celastrol (14), and the established MAGL
inhibitor pristimerin (15). All four derivatives failed to show any
inhibition of hABHD12 and the findings with pristimerin are in
agreement with those in the study by King et al. [17] where
pristimerin was tested against different endocannabinoid targets.
Poor inhibitory activity of triterpenoids 12–15 allowed us to
conclude that triterpene backbone was crucial for the hABHD12
inhibitor activity.
As betulinic acid (1), ursolic acid (4) and oleanolic acid (7) had
only minor differences in their inhibitory activities, neither the size
of the ring E (Figure S1) nor its substituents have a role in
hABHD12 inhibition. In order to establish additional structural
features that are critical for hABHD12 inhibition, we chose a
series of previously reported derivatives of betulinic acid (16–43
Table 1 and Figures 1–4, for compounds 44–68 see Table S3) for
further evaluation. Importance of the carboxyl group at position
17 was further verified by testing an aldehyde 16 which only
weakly inhibited hABHD12 (,30%) at 10 mM concentration
(Figure 1). When comparing two similar aldehydes (16 and 17),
the inhibition was enhanced to moderate level when hydroxyl
substituent at position 3 was replaced to carbonyl, i.e. a plain
hydrogen bond accepting group. An amide bond (20–22, Figure 1)
as well as an insertion of an ester (26–28, Figure 2) or ether (29,
Figure 2) similarly decreased inhibitor activity. When carboxyl
group was replaced with an oximino group (24, Figure 2), modest
inhibitory activity was observed (IC50 6.5 mM). Inhibitory activity
of the oxime 24 was retained by replacing hydroxyl group at
position 3 with another oximino group (25, Figure 2). When
carboxyl group at position 17 was retained and an oximino group
was added at position 3 (19, Figure 1), decreased inhibitory activity
was observed. However, it was interesting that compound 19 was
able to fully inhibit the enzyme whereas maximum inhibition of
the compound 24 was only 61%.
The effect of the modifications on the ring A on hABHD12
inhibitor activity are presented in the Figures 3–4 and Table S3.
As shown in the case of maslinic acid, an additional hydroxyl
Triterpenoids as Inhibitors of ABHD12
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e98286
Table 1. Inhibitor potency in hABHD12-HEK293 lysates for commercially available triterpenes (1–11) and triterpenoids (12–15) as
well as their calculated lipophilicity values (logD).
Compound General name
Remaining activity
at 10 mM % ± s.e.m. -logIC50±s.e.m. [IC50] (max inhibition) logD
1 (pH 7.4)
1 Betulinic acid 5.6060.182 [2.5 mM] 4.04
2 Betulin ,75 6.17
3 Lupeol NI 7.45
4 Ursolic acid ,30 5.7460.142 [1.8 mM] 3.98
5 Asiatic acid NI 1.62
6 a-Amyrin NI 7.39
7 Oleanolic acid ,20 5.8060.072 [1.6 mM] 3.99
8 Maslinic acid 5.9060.04 [1.3 mM] (89%) 2.92
9 Hederagenin 7863.0 2.71
10 b-Amyrin NI 7.40
11 a-Boswellic acid NI 3.84
12 CDDO NI 3.68
13 CDDO methyl ester NI 6.55
14 Celastrol NI 2.75
15 Pristimerin NI 5.47
1logD values have been calculated using ChemAxon Marvin 6.0 software.
2Valueas are -logIC506s.d., n= 2.
NI no inhibition.
Data are mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0098286.t001
Figure 1. Inhibitor potency in hABHD12-HEK293 lysates for compounds 16–23 as well as their calculated lipophilicity values (logD).
Data are mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0098286.g001
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group at the position 2 resulted in good inhibition. We synthesized
the corresponding betulinic acid derivative 32 (Figure 3) and
observed that the activity of this compound was similar to that of
the parent betulinic acid (1). Additional heterocyclic ring system
attached to the ring A generally gave good inhibition. For
example, when hydroxyl groups at positions 2 and 3 were
protected as an acetonide (31), modest inhibitory activity (IC50
7.5 mM) was observed. Replacement of a ring A with a lactam ring
(36) resulted in modest inhibitory activity (IC50 9.1 mM), however,
the lactam ring also decreased selectivity, as compound 35 also
inhibited MAGL (,50% inhibition at 10 mM concentration,
Table S1). Introduction of a pyridine or a pyrazine ring (40–43,
Figure 4) or an indole ring (33–34, Figure 3) revealed an
important structural feature. The position of a nitrogen atom in
the pyridine ring turned out to be important for the inhibitory
activity as the compound 41 showed improved activity over the
compound 40. Activity was further improved by replacing the
pyridine ring with an indole ring (33–34, Figure 3) or a pyrazole
(37, Figure 3). In fact, compound 33 was the most potent
compound of the entire series having an IC50 value of 0.9 mM
(maximum inhibition 65%). As evidenced by the total loss of the
inhibitory activity in the case of the indole-fused allobetulin
derivative 35 (Figure 3), the carboxyl group at position 17 was still
needed for inhibitory activity. However, one should also keep in
mind that the solubility of allobetulin derivative was very low.
Finally, poor inhibitory activity of the isoxazole 38 allowed us to
conclude that a functional group with a hydrogen bond donor or
acceptor at carbon 3 was crucial for ABHD12 inhibitory activity.
In summary, the above-described SAR studies allowed us to
identify four key determinants for hABHD12 inhibition potency
and efficacy. These key features played an important role in
building a pharmacophore model of ABHD12 that is described
later in this chapter. (i) Shape complementarity of the triterpene
skeleton accompanied with four axial methyl substituents likely
play an important role in inhibitor binding. Additional double
bonds within the skeleton (CDDO and celastrol) affect the overall
planar shape of triterpene scaffold, leading to total lack of
inhibitory activity. (ii) Carboxyl group at position 17 in triterpene
core structure is of crucial importance, as basically any modifica-
tion at this position reduced, or fully eliminated inhibitory activity.
It is known from previous studies that the carboxyl group at this
position is crucial also in many other biological targets [21–23].
(iii) Small, hydrophobic substituents at the position 4 are required,
as asiatic acid (5) and hederagenin (9) did not inhibit hABHD12.
(iv) As summarized in Figure S3, hydrogen bond donor or
acceptor attached to position 3 was a key feature required for high
inhibitory potency. This was further illustrated by pyridine and
pyrazine derivatives 40–42. Compounds 41 and 42 have a
nitrogen at this position and show moderate inhibitory activity
(IC50 values 6.7 and 3.6 mM, respectively). In contrast, no atom
Figure 2. Inhibitor potency in hABHD12-HEK293 lysates for compounds 24–30 as well as their calculated lipophilicity values (logD).
Data are mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0098286.g002
Triterpenoids as Inhibitors of ABHD12
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e98286
capable of hydrogen bonding is present in the compound 40,
causing dramatic decrease of inhibitory activity (34% inhibition at
10 mM). A good pair of compounds for comparison was 37 and
38. The pyrazole derivative 37 was one of the most potent
compounds in the series. On the other hand, when an aromatic
nitrogen was replaced by an oxygen (isoxazole 38), a complete loss
of the inhibitory activity was observed. This was due to the fact
that oxygen within an aromatic ring cannot form hydrogen bond.
The most promising synthetic compounds in the series were
compounds 33 and 34 which both have an indole ring attached to
ring A, and thus, a nitrogen atom at this crucial hydrogen bonding
position. The compound 34 has an electron donating methoxy
group at the indole ring which may cause tighter interaction
between indole nitrogen and amino acid residues of the enzyme.
In addition, good inhibitory activity of this methoxy derivative also
implies that there is additional space for bulkier substituents in this
direction. Strength of a hydrogen bond may also explain why these
compounds were equally potent in inhibiting hABHD12 activity
but their maximal inhibition was significantly different (65% and
100%, respectively). Similar trend in efficacy was observed with
the compounds 41 and 42, i.e. additional nitrogen in pyrazine
decreased efficacy (maximal inhibition 80 and 56%, respectively).
Collectively, the above data demonstrate the importance of a
hydrogen bond donor at position 3. However, as betulinic acid (1)
that can act both as a hydrogen bond acceptor and a donor, and
compound 18 that is a hydrogen bond acceptor, both showed
good inhibitory activity, we were able to conclude that both
hydrogen bond donor and acceptor are tolerated at this position.
The key finding that both hydrogen bond donor and acceptor at
position 3 are able to form good interactions with the enzyme led
us to hypothesize that these interactions might involve a serine
residue, possibly the catalytic serine (S246) of ABHD12, previously
identified by site-directed mutagenesis [4]. However, due to the
reversible nature of triterpenoid inhibition (see below), this
hypothesis could not be experimentally tested.
Triterpenoids inhibit hABHD12 in a reversible manner
There are no suitable functional groups in the triterpenoid
scaffold that could irreversibly react with catalytic residues of the
serine hydrolases. This has been previously shown with pristimerin
that inhibits MAGL in a reversible manner [17]. To test whether
the triterpenoids also reversibly inhibit hABHD12, we assessed
time-dependency of inhibitor potency following rapid, 40-fold
dilution of the enzyme-inhibitor complex. We determined the IC50
values for selected triterpenoids from kinetically recorded data at
time points 10, 20, 30, 60 and 90 minutes. A statistically
significant, time-dependent drop in inhibitor potency was evident
Figure 3. Inhibitor potency in hABHD12-HEK293 lysates for compounds 31–39 as well as their calculated lipophilicity values (logD).
Data are mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0098286.g003
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for the tested triterpenoids, indicating rapid dissociation of the
inhibitor from the enzyme’s active site (Figure S4). In contrast, the
IC50 values for the reference compound THL remained constant
regardless of the incubation time, indicating that within the time-
frame studied, the b-lactone irreversibly inhibited hABHD12.
A ligand-based pharmacophore model for ABHD12
Low structural homology to experimental template structures
prevented a creation of a comparative model of ABHD12 that
could have been used in docking studies. Before looking at the
SAR in more detail, we wished to clarify whether the chemical
structures of the in vivo substrate LPS, the irreversible inhibitor
THL, and the triterpene inhibitor betulinic acid could be aligned.
Interestingly, molecular superimposition disclosed that there were
striking similarities, not only in the topology and dimensions of the
three compounds, but also in the distance and orientation of the
functional groups (Figure S5). Encouraged by these findings, we
proceeded to the collected SAR data that included a total of 68
compounds of which 18 are classified as active and 50 as inactive.
Based on these compounds, we constructed a model that consists
of 14 pharmacophoric features (Figure 5). When a partial match of
11/14 was used, all 18 active triterpenoids satisfied the query and
only 4 false positives were found (false positive compounds:
betulin, asiatic acid, hederagenin and compound 16, false positive
rate = 0.08). It can be concluded that some inactive compounds
were structurally so close to the active compounds that they cannot
be easily ruled out by the means of common pharmacophoric
criteria.
Triterpenoids exhibit unprecedented selectivity towards
ABHD12 among the serine hydrolases
Triterpenoids possess a ‘‘universal’’ core structure that can be
recognized by many proteins. Therefore, the triterpenoids
reported in this paper are likely to have additional targets besides
Figure 4. Inhibitor potency in hABHD12-HEK293 lysates for compounds 40–43 as well as their calculated lipophilicity values (logD).
Data are mean 6 SEM from three independent experiments.
doi:10.1371/journal.pone.0098286.g004
Figure 5. Collection of the features used to define the
pharmacophoric model for the binding of the triterpenes to
the ABHD12. Color coding of pharmacophoric features: green,
hydrophobic site; magenta, acceptor site; cyan, donor site; gray cage,
ligand shape constraint. B. The best solution for the alignment of the
most active compound (33) to pharmacophore model (the same color
coding as above except the ligand surface omitted for the clarity).
doi:10.1371/journal.pone.0098286.g005
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ABHD12. Despite this, we were surprised to learn that the
representative inhibitors in the triterpenoid series did not hit other
targets of the endocannabinoid system including ABHD6, MAGL,
fatty acid amide hydrolase (FAAH) or the cannabinoid receptors
(Tables S1 and S2). We used activity-based protein profiling
(ABPP) with the catalytic serine-targeting probe TAMRA-FP to
unveil triterpenoid targets among the metabolic serine hydrolases
in lysates of hABHD12-HEK293 cells (Figure 6A–B). These
experiments revealed that the active triterpenoid 23 dose-
dependently inhibited probe labeling of hABHD12 whereas
compound 22 which was inactive in glycerol-based hydrolase
assays, lacked activity also in the ABPP assay. We extended the
ABPP studies to cover mouse brain membrane proteome and
found that compound 23 and maslinic acid (8) (but not the
inactive compound 22) selectively inhibited probe labeling of
ABHD12 in the brain proteome (Figure 6C). It is noteworthy that
with the exception of maslinic acid interfering with probe labeling
of an uncharacterized ,90 kDa protein, no additional targets
were evident for the triterpenoids among the brain membrane
serine hydrolases (Figure 6C). Thus, although the in vitro inhibitor
and substrate profiles of ABHD12 were previously shown to partly
overlap with those of ABHD6 and MAGL [4], ABHD12 appears
to be rather unique among these hydrolases, and more broadly so
also among the metabolic serine hydrolases, as it was the sole
serine hydrolase targeted by the triterpenoids in native brain
membrane proteome.
In conclusion, we report the discovery of the first phytocom-
pounds and their synthetic analogues that inhibit human and
mouse ABHD12. The studied compounds belong to the class of
triterpenoids that are known to possess wide-ranging therapeutic
effects. The best compounds fully inhibited hABHD12 with the
IC50 values in the submicromolar range. Further mechanistic
studies using representative compounds, including maslinic acid,
showed that ABHD12 inhibition was reversible. The compounds
did not inhibit the endocannabinoid hydrolases such as ABHD6,
MAGL and FAAH, nor did they show appreciable activity
towards the cannabinoid receptors. Activity-based protein profil-
ing of mouse brain membrane proteome with a serine hydrolase-
targeting probe revealed that the triterpenoids selectively inhibited
ABHD12 with no additional targets evident among the metabolic
serine hydrolases. Thus contrary to preconceived thinking, the
triterpenoids showed unprecedented selectivity for ABHD12, not
only over other serine hydrolases but also over cannabinoid
receptors. Finally, using our SAR analysis with the presently
described betulin-based compound series, we have disclosed
important structural features required for ABHD12 inhibition.
We have used these data in the development of the first
pharmacophore model for ABHD12. This model should be useful
in further studies aiming at the discovery of novel lead structures
for ABHD12 inhibitors.
Methods
Chemistry
Compounds 1, 3–7, 9–11 and 14–15 were purchased from
Sigma-Aldrich and compounds 2, 8 and 12–13 from Cayman
Chemical Company. Commercially available compounds were
used without further purification or structural verification.
Synthesis procedures and structural verification of the compounds
16–43 (with the exception of compound 32 and 40) have been
previously reported [24–27]. Structures of inactive compound 44–
68 have been presented in Table S3. Synthesis procedures and
structural verification have been previously reported (with the
exception of the compound 68) [24–27].
Synthesis procedures (compounds 32, 40, 68)
2b,3b-Dihydroxylup-20(29)-en-28-oic acid (32). A mixture
of betulonic acid (68 mg, 0.15 mmol) and potassium tert-butoxide
(604 mg, 5.40 mmol) in tert-butanol (7.0 mL) was stirred with
constant air flow at 40uC for 2 h. Then 1 M hydrochloric acid was
added and the resulting mixture was extracted with EtOAc several
times. The combined organic phases were washed with water and
brine, dried over anhydrous Na2SO4 and evaporated to give a
white crystalline solid 2-hydroxy-3-oxolupa-1(2),20(29)-dien-28-oic
acid (69 mg, 98%). 1H NMR (300 MHz, CDCl3) d 6.44 (s, 1H),
4.75 (s, 1H), 4.63 (s, 1H), 3.11–2.93 (m, 1H), 2.38–2.15 (m, 2H),
1.70 (s, 3H), 1.52 (m, 15H), 1.20 (s, 3H), 1.12 (s, 3H), 1.10 (s, 3H),
1.01 (s, 3H), 0.98 (s, 3H). A solution of 2-hydroxy-3-oxolupa-
1(2),20(29)-dien-28-oic acid (69 mg, 0.15 mmol) in tetrahydrofu-
ran (3 mL) and ethanol (1 mL) was kept on ice bath and NaBH4
(18 mg, 0.48 mmol) was added to the solution. The resulting
mixture was stirred at room temperature for 2 h. Then 1 M
hydrochloric acid was added to the reaction mixture, and it was
extracted with EtOAc, washed with water and brine, dried over
anhydrous Na2SO4, and evaporated. The crude product was
purified with SiO2 column chromatography (10–100% EtOAc/n-
hexane) to yield 2b,3b-dihydroxylup-20(29)-en-28-oic acid as a
white crystalline solid (25 mg, 35%). 1H NMR (300 MHz,
(CD3)2CO) d 4.73 (m, 1H), 4.60 (m, 1H), 4.01 (m, 1H), 3.49 (br
s, 1H), 3.13 (d, J = 4.0 Hz, 1H), 3.06 (m, 1H), 2.32 (m, 2H), 2.13
(dd, J= 14.2, 2.9 Hz, 1H), 1.94 (m, 2H), 1.70 (s, 3H), 1.57–1.36
(m, 9H), 1.19 (s, 3H), 1.02 (s, 3H), 0.98 (s, 6H), 0.97 (s, 3H); 13C
NMR (75 MHz, (CD3)2CO) d 177.7, 151.8, 110.2, 78.8, 72.0,
57.0, 56.5, 52.0, 50.2, 48.2, 45.6, 43.6, 41.9, 39.3, 39.2, 38.0, 37.8,
35.4, 33.1, 31.6, 30.6, 26.7, 22.1, 19.7, 19.1, 17.9, 17.8, 16.8, 15.3.
NMR spectral data is consistent with those previously reported
[28].
Lupa-2,20(29)-dieno[2,3-b]pyridin-28-oic acid. (i) Benzyl
betulonate (40). To a mixture of betulonic acid (0.500 g,
1.10 mmol) and K2CO3 (304 mg, 2.20 mmol) in DMF (10 mL) at
55uC, benzyl bromide (244 mg, 1.43 mmol) was added dropwise.
After stirring the reaction mixture at 55uC overnight, water was
added, and the resulting solution was extracted with EtOAc. The
organic phase was washed with water for several times and
subsequently with brine, dried over anhydrous Na2SO4 and
evaporated. The crude product was purified with SiO2 column
chromatography (20–50% EtOAc/n-hexane) to yield benzyl
betulonate as a white crystalline solid (388 mg, 65%). 1H NMR
(300 MHz, CDCl3) d 7.35 (m, 5H), 5.12 (q, J= 12.3 Hz, 2H), 4.72
(s, 1H), 4.60 (s, 1H), 3.16–2.93 (m, 1H), 2.35 (m, 4H), 1.97–1.79
(m, 3H), 1.66 (s, 3H), 1.49–1.19 (m, 15H), 1.06 (s, 3H), 1.01 (s,
3H), 0.95 (s, 3H), 0.90 (s, 3H), 0.79 (s, 3H). (ii) Benzyl
2-hydroxy-3-oxolupa-1(2),20(29)-dien-28-oate. A mixture
of benzyl betulonate (822 mg, 1.55 mmol) and potassium tert-
butoxide (2.38 g, 43.8 mmol) in tert-butanol (50 mL) was stirred
with constant air flow at 40uC for 2 h. Then 1 M hydrochloric
acid was added and the resulting mixture was extracted with
EtOAc several times. The combined organic phases were washed
with water and brine, dried over anhydrous Na2SO4 and
evaporated to give a white crystalline solid benzyl 2-hydroxy-3-
oxolupa-1(2),20(29)-dien-28-oate (817 mg, quant.). 1H NMR
(300 MHz, CDCl3) d 7.43–7.28 (m, 4H), 5.13 (q, J = 12.3 Hz,
2H), 4.72 (s, 1H), 4.61 (s, 1H), 3.01 (s, 1H), 2.25 (m, 3H), 1.65 (s,
3H), 1.62–1.31 (m, 14H), 1.18 (s, 3H), 1.09 (s, 6H), 1.18 (s, 3H),
1.09 (s, 3H), 0.96 (s, 3H), 0.79 (s, 3H). (iii) Benzyl 2a,3b-
dihydroxylup-20(29)-en-28-oate. A solution of benzyl 2-
hydroxy-3-oxolupa-1(2),20(29)-dien-28-oate (817 mg, 1.46 mmol)
in tetrahydrofuran (20 mL) and ethanol (4 mL) was kept on ice
bath and NaBH4 (159 mg, 2.88 mmol) was added to the solution.
Triterpenoids as Inhibitors of ABHD12
PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e98286
The resulting mixture was stirred at room temperature for 1.5 h.
Then 1 M hydrochloric acid was added to the reaction mixture,
and it was extracted with EtOAc, washed three times with water, a
saturated aqueous solution of NaHCO3, water and brine, dried
over anhydrous Na2SO4, and evaporated. The crude product was
purified with SiO2 column chromatography (10–50% EtOAc/n-
hexane) to yield benzyl 2a,3b-dihydroxylup-20(29)-en-28-oate as a
white crystalline solid (605 mg, 74%). 1H NMR (300 MHz,
CDCl3) d 7.50–7.26 (m, 5H), 5.12 (q, J= 12.3 Hz, 2H), 4.72 (s,
1H), 4.59 (s, 1H), 4.08 (d, J= 3.4 Hz, 1H), 3.17 (d, J = 4.0 Hz,
1H), 3.02 (d, J= 4.6 Hz, 1H), 2.43–2.05 (m, 2H), 1.88 (m, 4H),
1.67 (s, 3H), 1.58–1.18 (m, 14H), 1.17–1.02 (m, 7H), 0.97 (s, 6H),
0.93 (s, 3H), 0.76 (s, 3H). (iv) A mixture of benzyl 2-oxolup-
20(29)-en-28-oate and benzyl 3-oxolup-20(29)-en-28-oate.
A solution of benzyl 2a,3b-dihydroxylup-20(29)-en-28-oate
(605 mg, 1.07 mmol) and p-toluenesulfonyl chloride (287 mg,
Figure 6. Competitive ABPP to unveil triterpenoid targets among the serine hydrolases in proteomes of HEK293 cell lysates (A–B)
and mouse brain membranes (C). Lysates (25 mg) or membranes (100 mg) were treated for 1 h with DMSO or the indicated concentrations of the
inhibitors, after which TAMRA-FP labelling was conducted for 5 min (lysates) or for 1 hour (membranes), as described in Methods. The proteins were
resolved in 10% SDS-PAGE together with protein standards. TAMRA-FP labeling was visualized after in-gel fluorescence imaging as described in
experimental procedures. Molecular weight markers are shown in both gel images. A. Transient expression of hABHD12 in HEK293 cells results in the
appearance of a ,46 kDa protein band (black arrow), comigrating together with an endogenous serine hydrolase with similar size. The endogenous
band is weakly visible in Mock lysates and does not correspond to ABHD12 [4]. Note that probe labeling to hABHD12 is fully prevented by THL
(10 mM), it is also dose-dependently inhibited by compound 23 whereas compound 22 is ineffective. B. Quantitative data (mean 6 SEM) on the
effects of selected triterpenoids on probe labeling of the hABHD12 band (black arrow in A) combined from three independent experiments with
hABHD12-HEK lysates. Statistical differences in band intensities were tested using one-way ANOVA, followed by Tukey’s multiple comparison test
(**P,0.01 and ***P,0.001). C. ABHD12 is the sole triterpenoid target among the serine hydrolases in mouse brain membrane proteome. THL (10 mM)
was used as a positive control and consistent with previous data [1,34,35], THL prevented TAMRA-FP labeling of serine hydrolases migrating at
,63 kDa (BAT5), ,46 kDa (ABHD12) and ,33 kDa (ABHD6). Note that compound 23 and maslinic acid (compound 8) dose-dependently inhibit
TAMRA-FP labeling of ABHD12 already at 20 mM whereas compound 22 is ineffective, even at 200 mM concentration. Note also that with the
exception of heightened TAMRA-FP labeling of an unidentified serine hydrolase migrating at,90 kDa (indicated by the asterix), no additional targets
are evident for maslinic acid or compound 23 among the metabolic serine hydrolases. The gel is representative from three independent ABPP runs
with similar outcome.
doi:10.1371/journal.pone.0098286.g006
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1.50 mmol) in anhydrous pyridine (10 mL) was stirred at 30uC for
6 h and after that stirring was continued at 60uC for 18 h. The
reaction mixture was cooled to room temperature and 1 M
hydrochloric acid was added. The resulting mixture was extracted
with EtOAc, washed three times with water, a saturated aqueous
solution of NaHCO3 and brine, dried over anhydrous Na2SO4
and evaporated. The crude product was purified with SiO2
column chromatography (5–20% EtOAc/n-hexane) to yield a
mixture of two compounds, benzyl 2-oxolup-20(29)-en-28-oate
and benzyl 3-oxolup-20(29)-en-28-oate as a white crystalline solid
(339 mg, 58%). 1H NMR (300 MHz, CDCl3) d 7.33 (m, 5H),
5.29–4.95 (m, 2H), 4.72 (s, 1H), 4.59 (s, 1H), 3.17–2.87 (m, 1H),
2.57–2.05 (m, 4H), 2.06–1.79 (m, 3H), 1.68 (s, 3H), 1.54–1.13 (m,
17H), 1.05 (s, 2H), 1.02 (s, 2H), 1.00 (s, 2H), 0.97 (s, 2H), 0.94 (s,
2H), 0.89 (s, 2H), 0.84 (s, 3H), 0.80 (s, 2H), 0.78 (s, 2H), 0.74 (s,
2H). (v) A mixture of betulonic acid and 2-oxolup-20(29)-
en-28-oic acid. To a solution of benzyl 2-oxolup-20(29)-en-28-
oate and benzyl 3-oxolup-20(29)-en-28-oate (330 mg, 0.60 mmol)
in tetrahydrofuran (15 mL) was added 10% Pd on carbon (30 mg)
under argon. Argon atmosphere was replaced with H2, and the
resulting mixture was stirred at room temperature for 4.5 h. The
reaction mixture was filtered through a thin layer of Celite, and
the resulting filtrate was evaporated. The crude product was
purified with SiO2 column chromatography (10–30% EtOAc/n-
hexane) to yield a mixture of betulonic acid and 2-oxolup-20(29)-
en-28-oic acid as a white crystalline solid (220 mg, 80%). 1H NMR
(300 MHz, CDCl3) d 4.74 (s, 1H), 4.61 (s, 1H), 2.99 (m, 1H), 2.60–
2.11 (m, 5H), 2.02–1.78 (m, 3H), 1.72 (s, 4H), 1.57–1.14 (m, 17H),
1.07 (s, 1H), 1.04 (s, 2H), 1.01 (s, 2H), 0.99 (s, 2H), 0.97 (s, 2H),
0.93 (s, 1H), 0.92 (s, 2H), 0.85 (s, 2H), 0.83 (s, 2H). (vi) Lupa-
2,20(29)-dieno[2,3-b]pyridin-28-oic acid. A mixture of
betulonic acid and 2-betulonic acid (220 mg, 0.48 mmol) as well
as propargylamine (53 mg, 0.97 mmol) and CuCl2 (27 mg,
0.16 mmol) in ethanol (8 mL) was refluxed for 17 h. The resulting
solution was filtered and evaporated, and the crude product was
purified with SiO2 column chromatography (10–50% EtOAc/n-
hexane) to give lupa-2,20(29)-dieno[2,3-b]pyridin-28-oic acid (35)
as a crystalline product (37 mg, 21%).1H NMR (300 MHz,
CDCl3) d 8.37 (1H, dd, J= 4.8, 1.6 Hz, H-31), 7.68–7.61
(1H,m, H-33), 7.13 (1H, dd, J = 8.0, 4.8 Hz, H-32), 4.75 (1H, s,
H-29), 4.63 (1H, s, H-29), 3.07 (2H, m, H-1), 2.48 (2H, m) 2.31
(2H, m, H-11), 1.98 (2H, m), 1.71 (3H s, H-30), 1.54 (m, 13H),
1.27 (m, 2H), 1.23 (3H, s, H-23/24), 1.18 (3H, s, H-24/23), 1.02
(3H, s, H-27), 1.01 (3H, s, H-26), 0.80 (3H, s, H-25); 13C NMR
(75 MHz, CDCl3) d 180.9 (C-28), 155.0 (C-2), 150.6 (C-20), 146.1
(C-31), 141.0 (C-4), 135.7 (C-33), 121.9 (C-32), 110.0 (C-29), 56.6,
53.0 (C-5), 49.4, 49.0 (C-9), 48.8 (C-1), 47.1 (C-19), 42.7, 40.7 (C-
13), 38.7, 37.3, 37.1, 36.8 (C-10), 33.6, 33.2 (C-23/24), 32.4 (C-
11), 30.9, 29.9, 25.7 (C-24/23), 21.5, 20.2, 19.7 (C-30), 16.2 (C-
25), 15.9 (C-26), 14.9 (C-27); FTIR (n, cm21): 872, 1132, 1159,
1178, 1449, 1708, 2869, 2943; HRMS: m/z calcd for C33H48NO2:
490.3685, found 490.3688 [M+H]+.
1-(1H-1,2,4-Triazol-1-yl)betulonone (68). Solution of be-
tulonic acid (0.10 g, 0.22 mmol) and 1,19-carbonyl-di-(1,2,4-
triazole) (216 mg, 1.30 mmol) in tertrahydrofuran was refluxed
for 20 h. Solvent was evaporated and the crude product was
purified with SiO2 column chromatography (10-100% EtOAc/n-
hexane) to yield 1-(1H-1,2,4-triazol-1-yl)betulonone as white solid
(55 mg, 49%). 1H NMR (300 MHz, CDCl3) d 8.91 (s, 1H), 7.98 (s,
1H), 4.76 (s, 1H), 4.64 (s, 1H), 3.08–2.85 (m, 2H), 2.73–2.30 (m,
4H), 1.90 (m, 1H), 1.71 (s, 3H), 1.38 (m, 10H), 1.06 (s, 3H), 1.01 (s,
6H), 0.96 (s, 3H), 0.94 (s, 3H); 13C NMR (75 MHz, CDCl3) d
218.0, 173.6, 152.4, 150.1, 145.3, 110.2, 58.6, 55.2, 51.2, 50.3,
47.5, 45.8, 42.6, 40.9, 39.8, 37.4, 37.1, 36.4, 34.3, 33.8, 31.7, 30.7,
30.0, 26.8, 25.7, 21.7, 21.2, 19.8, 19.6, 16.2, 16.0, 14.8; FTIR (n,
cm21): 670, 897, 1178, 1271, 1356, 1706, 1736, 2872, 2940;
HRMS: m/z calcd for C32H47N3NaO2: 528.3566, found 528.3563
[M+Na+] [29].
Determination of endocannabinoid hydrolase activity
Glycerol liberated from 1-AG hydrolysis was determined with a
sensitive fluorescent assay using lysates of HEK293 cells with
transient overexpression of hABHD12, hABHD6 or hMAGL,
essentially as previously described [4]. Briefly, following 30 min
incubation of DMSO/inhibitor (1 ml) together with hABHD12-
HEK293, hABHD6-HEK293 or hMAGL-HEK293 lysates (99 ml,
0.3 mg protein/well) in TEMN-BSA buffer [50 mM Tris-HCl,
pH 7.4, 1 mM EDTA, 5 mM MgCl2, 100 mM NaCl, 0.5% (w/v)
fatty acid-free BSA], 1-AG [12.5 mM final concentration,
containing additionally 1% EtOH (v/v)] in glycerol assay mix
prepared in TEMN-BSA buffer was added (100 ml) and the
incubation continued for 90 min at RT. Fluorescence (lex 530;
lem 590 nm) was monitored using a Tecan Infinite M200 plate
reader (Tecan Group Ltd., Ma¨nnedorf, Switzerland). Inhibitory
activities of selected compounds towards FAAH were determined
using membranes of hFAAH overexpressing COS-7 cells,
essentially as previously described [30]. The final incubation
volume (100 mL) contained 1 mg of protein and the substrate
concentration was 20 mM (10 nM of 3H-anandamide having
specific activity of 60 Ci/mmol and concentration of 1 mCi/mL).
Reversibility testing
Reversibility testing was carried out as previously described
[31]. Briefly, DMSO/inhibitor (0.5 ml) was incubated together
with hABHD12-HEK293 lysate (4.5 ml, 0.3 mg protein/well) in
TEMN-BSA buffer for 30 min. After this, a 40-fold dilution of
enzyme-inhibitor complex was brought about by addition of the
substrate [1-AG, 12.5 mM final concentration, containing addi-
tionally 1% EtOH (v/v)] in 195 ml of glycerol assay mix and
fluorescence was kinetically monitored at 10 min intervals for
90 min at RT. Five to six inhibitor concentrations were included
to cover the entire dose-response range and the IC50 values were
determined at time-points 10, 20, 30, 60 and 90 min.
Determination of ABHD12 activity using a LC-MS assay
Betulinic acid, oleanolic acid, ursolic acid as well as the
compounds 18 and 25 at concentrations .1025 M were found to
interfere with the routine fluorescent assay, and therefore, the
dose-response curves for these compounds were determined using
LC-MS. The fluorescent glycerol assay was mimicked otherwise
but instead of assaying glycerol, utilization of 1-AG and
concomitant formation of AA was monitored by LC-MS analysis.
Briefly, after 30 minutes preincubation of DMSO/inhibitor (1 ml)
with hABHD12-HEK293 cell lysate (99 ml, 0.3 mg protein/well) in
TEMN-BSA buffer, pH 7.4, 1-AG [12.5 mM final concentration,
containing additionally 1% EtOH (v/v)] in TEMN-BSA buffer
(100 ml) was added and the incubation continued for 90 min at
RT. Enzymatic reaction was stopped by adding 400 mL of cold
11 mM H3PO4 in acetonitrile. 150 mL aliquots were filtered using
Captiva 96-well filter plate (0.2 mm, Agilent Technologies, USA)
into the Captiva 96-well collection plate (Agilent Technologies,
USA) containing 50 mL of 0.1% formic acid in H2O. The
collection plate was centrifuged at 4uC for 10 minutes and the
samples were analyzed by LC-MS. HPLC system consisted of an
Agilent 1200 Series Rapid Resolution LC System (Agilent
Technologies, Waldbronn, Germany) with a solvent micro
vacuum degasser, a binary pump, a thermostatted column
compartment, and an autosampler. The mass analysis was made
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with an Agilent 6410 Triple Quadrupole MS equipped with an
electrospray ionization (ESI) source (Agilent Technologies, Palo
Alto, CA, USA). Five microliters of the sample solution were
injected onto a reversed-phase HPLC column (Zorbax Eclipse
XDB-C18 Rapid Resolution HT 2.1 mm650 mm, 1.8 mm)
(Agilent Technologies, Palo Alto, CA, USA) using an isocratic
mobile phase consisting of 0.1% formic acid in a solution of H2O
and methanol (20:80 v/v) delivered at 0.5 mL/min. Column
temperature was maintained at 50uC and the autosampler tray
temperature was set at 4uC. The following ionization conditions
were used for 1-AG: positive ESI mode, drying gas (nitrogen)
temperature 300uC, drying gas flow rate 8 L/min, nebulizer
pressure 40 psi, and capillary voltage 4000 V. The following
ionization conditions were used for AA: negative ESI mode,
drying gas (nitrogen) temperature 300uC, drying gas flow rate
8 L/min, nebulizer pressure 40 psi, and capillary voltage 4000 V.
Analyte detection was performed using multiple reaction moni-
toring (MRM) with the following transitions: m/z 379R 287 for 1-
AG and m/z 303R 303 for AA. Fragmentor voltage and collision
energy for 1-AG and AA were 130 V/8 V and 175 V/2 V,
respectively. Retention times for 1-AG and AA were 2.4 and
3.4 min, respectively. In addition, the 2-AG positional isomer is
chromatographically separated from 1-AG with retention time
2.1 min, and the peak areas of 1-AG and 2-AG were subsequently
combined for all quantitative analyses reported and are thus
collectively termed ‘‘1-AG’’. The calibration range of 0.1–
2,000 ng/mL and 0.1–1,000 ng/mL was prepared for monitored
1-AG and AA, respectively. The lower limit of quantification
(LLOQ) for both analytes, 1-AG and AA, was 1.0 ng/mL.
Cannabinoid receptor activity
The CB1 and CB2 receptor activity of the selected compounds
(10 mM) were measured using the GTPcS binding assay according
to the previously described methods [32,33].
Activity-based protein profiling (ABPP) of serine
hydrolases
Competitive ABPP using HEK293 cell lysates and mouse brain
membranes was conducted to visualize effects of selected
triterpenoids on the binding of the active site serine-targeting
fluorescent fluorophosphonate probe TAMRA-FP following out-
lines of previous protocols [4,31]. Briefly, lysates (25 mg) of
HEK293 cells with or without (Mock) hABHD12 overexpression
or mouse wholebrain membranes (100 mg) were treated for 1 h
with DMSO or the inhibitor, after which TAMRA-FP labelling
was conducted for 5 min (lysates) or 1 hour (membranes) at RT
(final probe concentration 2 mM). The reaction was quenched by
addition of gel loading buffer (followed by boiling for 5 min in the
case of lysates), after which 10 mg protein (10 ml) was loaded per
lane and the proteins were resolved in 10% SDS-PAGE together
with standards. TAMRA-FP labeling was visualized (lex 552; lem
575 nm) by a fluorescent reader (FLA-3000 laser fluorescence
scanner, Fujifilm, Tokyo, Japan). The intensity of bands was
quantified using ImageJ, a freely available image analysis software
(http://rsbweb.nih.gov/ij/).
Molecular modelling
Structures of small molecules were prepared using the LigPrep
module Schro¨dinger’s Maestro software package (Schro¨dinger
Release 2013-2: Maestro version 9.5, LigPrep version 2.7,
MacroModel, version 10.1, Schro¨dinger, LLC, New York, NY).
Deprotonated forms of the carboxylic acids were used because that
would be the predominant form of such structures at the
physiological pH. The conformational database was constructed
using the conformational search with default torsional sampling
settings (MCMM) embedded to Macromodel module of Maestro.
The full dataset of 42 triterpenoids studied here resulted in a
database of 1703 conformations. The pharmacophore model was
constructed using Molecular Operating Environment (MOE)
software, version 2013.08 (Chemical Computing Group Inc.,
Canada). Active structures were overlaid using flexible alignment
and the pharmacophoric elements were defined using compounds
23 and 33 as main templates. Nine hydrophobic features were
used to describe the planar shape of the lupane skeleton. Three
hydrogen bond acceptor features were defined using the carboxyl
group at position 17, which was found to provide a good match for
all active structures including also groups such as oxime and
aldehyde substructures. In the case of substituents in the position 3
of the lupane skeleton both hydrogen bond donor and accepting
groups can be found. We used compound 33 for placement of the
hydrogen bond donating site and compound 23 for adding the
hydrogen bond acceptor site. An additional acceptor site was
needed for covering compounds having hydroxyl group in the
position 3. Finally, a ligand shape constraint was defined using the
compound 34 as template in order to rule out bigger inactive
structures such as esters in the position 17. In the final model, two
partial hit constraints (at least one) were added for the groups of
features describing hydrogen bond interactions at the positions 3
and 17.
Data analysis
The inhibitor dose-response curves and IC50 values derived
thereof were calculated from nonlinear regressions using Graph-
Pad Prism 5.0 for Windows (GraphPad Software, San Diego
California USA, www.graphpad.com) and the results are present-
ed as mean 6 S.E.M. of at least three independent experiments
performed in duplicate. Statistical comparisons between
hABHD12 band intensities in the ABPP study (Figure 6B) and
between the IC50 values in the reversibility study (Figure S4) were
tested using one-way ANOVA, followed by Tukey’s multiple
comparison test with p,0.05 considered as statistically significant
(*P,0.05, **P,0.01, and ***P,0.001).
Ethics statement
For ABPP experiments (Figure 6C) and cannabinoid receptor
activity assays (Table S2), membranes prepared from brain tissue
of 4-week-old male rodents were used. The animals were obtained
from the National Laboratory Animal Centre, University of
Eastern Finland. Approval for the harvesting of animal tissue was
obtained from the local welfare officer of the University of Eastern
Finland. No further ethical approval was required, as the
experiments did not involve any in vivo treatment.
Supporting Information
Figure S1 Established natural substrates (LPS, lysophosphati-
dylserine; 1(3)-AG, 1(3)-arachidonoyl glycerol) and inhibitors of
ABHD12 (THL, tetrahydrolipstatin; MAFP, methyl arachidonyl
fluorophosphonate), as well as general structure and numbering
system of the lupane skeleton.
(PDF)
Figure S2 Chemical structures of commercial compounds 1–15.
(PDF)
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Figure S3 Hydrogen bond donor or acceptor at the position 3 is
one of the key determinants for the inhibitory activity of betulinic
acid derivatives towards hABHD12.
(PDF)
Figure S4 Reversibility of hABHD12 inhibition by the triterpe-
noids. Fast 40-fold dilution of inhibitor-treated hABHD12-
HEK293 lysate preparation (see experimental procedures for
further details) results in time-dependent drop of inhibitor potency,
as evidenced for the triterpenoids 8 (maslinic acid), 33 and 34. In
contrast, the potency for the established irreversible serine
hydrolase inhibitor THL (orlistat) does not change in a statistically
significant manner during the time-course of this study. Due to low
signal-to-noise ratio, no reliable data could be obtained for
compound 34 and THL at time-point 10 min; therefore these data
points are not presented. Data are mean 6 SEM from three
independent experiments. Statistical differences between IC50
values at the earliest (10 or 20 min) and other time-points were
tested using one-way ANOVA, followed by Tukey’s multiple
comparison test (*P,0.05, **P,0.01 and ***P,0.001).
(PDF)
Figure S5 Lysophosphatidylserine (LPS, orange carbons, panel
A), the in vivo substrate of ABHD12, and tetrahydrolipstatin (THL,
green carbons, panel B), the irreversible inhibitor of ABHD12,
superimposed with the reversible inhibitor betulinic acid (gray
carbons). LPS and THL were modeled in an extended
conformation and the hydrocarbon chains have been partly faded
out. Note that even though the overall shapes of the molecules are
quite different, alignment shows that the topological distance and
orientation of the important functional moieties is surprisingly
similar. Namely, carboxylic acid group of LPS and formyl group of
THL both align with the carboxyl group of betulinic acid (dark
gray circles). In addition, hydroxyl group of betulinic acid aligns
with ester carbonyl of LPS and lactone carbonyl of THL (light
gray circles).
(PDF)
Table S1 Inhibitory activity of selected triterpenoids against
hABHD6, hMAGL and hFAAH.
(PDF)
Table S2 Activity of selected compounds at CB1 and CB2
receptors. Compounds were tested at 10 mM concentration.
(PDF)
Table S3 Chemical structures of tested compounds 44–67 that
do not markedly inhibit hABHD12 when tested at 10 mM
concentration.
(PDF)
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